Cochrane · systematic review · CD010649
Pro‐coagulant haemostatic factors for the prevention and treatment of bleeding in people without haemophilia
Fabes, J, Brunskill, SJ, Curry, N, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
InjuriesAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
22
current version
GRADE rated
22
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 9.1%Low 15 · 68.2%Moderate 4 · 18.2%High 1 · 4.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
FIBRINOGEN: Therapeutic trials: intervention compared to inactive Control for the prevention and treatment of bleeding in participants without haemophilia
Population: the prevention and treatment of bleeding in patients without haemophilia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Up to 28 days following admission FIBRINOGEN: Therapeutic trials: intervention vs inactive Control | RR 1.46 [0.71, 2.99] | 2 studies · 97 participants | Moderate |
All‐cause mortality In‐hospital mortality up to 30 days post‐operatively FIBRINOGEN: Therapeutic trials: intervention vs inactive Control | RR 5 [0.25, 102] | 1 study · 120 participants | Low Downgraded: imprecision |
All‐cause mortality Up to 6 weeks post‐natally FIBRINOGEN: Therapeutic trials: intervention vs inactive Control | no estimate extracted | 2 studies · 294 participants | Low Downgraded: imprecision |
All‐cause mortality Up to 46 days post‐operatively FIBRINOGEN: Therapeutic trials: intervention vs inactive Control | RR 0.23 [0.05, 1.01] | 2 studies · 213 participants | High |
FIBRINOGEN: Therapeutic trials: intervention compared to haemostatically active control for the prevention and treatment of bleeding in participants without haemophilia
Population: the prevention and treatment of bleeding in patients without haemophilia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Up to 7 days post‐operatively or hospital discharge FIBRINOGEN: Therapeutic trials: intervention vs haemostatically active control | no estimate extracted | 1 study · 63 participants | Moderate Downgraded: imprecision |
All‐cause mortality Up to 28 days post‐operatively FIBRINOGEN: Therapeutic trials: intervention vs haemostatically active control | no estimate extracted | 1 study · 20 participants | Low Downgraded: risk of bias, imprecision |
All‐cause mortality Up to 30 days post‐operatively FIBRINOGEN: Therapeutic trials: intervention vs haemostatically active control | RR 0.95 [0.06, 14.3] | 1 study · 43 participants | Low Downgraded: imprecision |
FIBRINOGEN: Prophylactic trials: intervention compared to inactive control for the prevention and treatment of bleeding in participants without haemophilia
Population: the prevention and treatment of bleeding in patients without haemophilia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Venous thromboembolic events Up to 30 days post‐operatively FIBRINOGEN: Prophylactic trials: intervention vs inactive control | no estimate extracted | 2 studies · 122 participants | Low Downgraded: risk of bias, imprecision |
Arterial thrombotic events Up to 4 days post‐operatively FIBRINOGEN: Prophylactic trials: intervention vs inactive control | no estimate extracted | 2 studies · 80 participants | Moderate Downgraded: imprecision |
Arterial thrombotic events Up to 30 days post‐operatively FIBRINOGEN: Prophylactic trials: intervention vs inactive control | RR 0.33 [0.01, 8.02] | 1 study · 116 participants | Low Downgraded: risk of bias, imprecision |
Arterial thrombotic events ‐ up to 30 days post‐operatively FIBRINOGEN: Prophylactic trials: intervention vs inactive control | no estimate extracted | 2 studies · 122 participants | Low Downgraded: risk of bias, imprecision |
Venous thrombotic events Up to 4 days post‐operatively FIBRINOGEN: Prophylactic trials: intervention vs inactive control | no estimate extracted | 2 studies · 80 participants | Moderate Downgraded: imprecision |
FIBRINOGEN: Prophylactic trials: intervention compared to haemostatically active control for the prevention and treatment of bleeding in participants without haemophilia
Population: the prevention and treatment of bleeding in patients without haemophilia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Arterial thromboembolic events FIBRINOGEN: Prophylactic trials: intervention vs haemostatically active control | no estimate extracted | 1 study · 49 participants | Low Downgraded: imprecision |
Arterial thromboembolic events ‐ Duration of hospital stay (whole population) FIBRINOGEN: Prophylactic trials: intervention vs haemostatically active control | no estimate extracted | 1 study · 49 participants | Low Downgraded: imprecision |
Venous thromboembolic events FIBRINOGEN: Prophylactic trials: intervention vs haemostatically active control | no estimate extracted | 1 study · 49 participants | Low Downgraded: imprecision |
Venous thromboembolic events Duration of hospital stay (whole population) FIBRINOGEN: Prophylactic trials: intervention vs haemostatically active control | no estimate extracted | 1 study · 49 participants | Low Downgraded: imprecision |
FXIII: Prophylactic trials: intervention compared to inactive control for the prevention and treatment of bleeding in participants without haemophilia
Population: the prevention and treatment of bleeding in patients without haemophilia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Arterial thromboembolic events Up to 5 to 7 weeks post‐operatively FXIII: Prophylactic trials: intervention vs inactive control | RR 0.67 [0.28, 1.62] | 2 studies · 282 participants | Low Downgraded: risk of bias |
Arterial thromboembolic events Up to 30 days post‐operatively FXIII: Prophylactic trials: intervention vs inactive control | RR 3 [0.14, 66.53] | 1 study · 22 participants | Low Downgraded: imprecision |
Arterial thromboembolic events Post‐operatively FXIII: Prophylactic trials: intervention vs inactive control | RR 0.2 [0.01, 3.97] | 1 study · 50 participants | Very low Downgraded: risk of bias, imprecision |
Venous thromboembolic events ‐ Up to 5 to 7 weeks post‐operatively FXIII: Prophylactic trials: intervention vs inactive control | RR 0.93 [0.06, 14.67] | 2 studies · 282 participants | Low Downgraded: risk of bias |
Venous thromboembolic events Up to 30 days post‐operatively FXIII: Prophylactic trials: intervention vs inactive control | RR 3 [0.14, 66.53] | 1 study · 22 participants | Low Downgraded: imprecision |
Venous thromboembolic events Post‐operatively FXIII: Prophylactic trials: intervention vs inactive control | no estimate extracted | 1 study · 50 participants | Very low Downgraded: risk of bias, imprecision |